Last reviewed · How we verify

Diet+pravastatin

Mitsukoshi Health and Welfare Foundation · FDA-approved active Small molecule

A combination therapy that uses dietary intervention alongside pravastatin, a statin that inhibits HMG-CoA reductase to lower cholesterol synthesis.

A combination therapy that uses dietary intervention alongside pravastatin, a statin that inhibits HMG-CoA reductase to lower cholesterol synthesis. Used for Hypercholesterolemia, Cardiovascular disease prevention.

At a glance

Generic nameDiet+pravastatin
SponsorMitsukoshi Health and Welfare Foundation
Drug classStatin (HMG-CoA reductase inhibitor)
TargetHMG-CoA reductase
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Pravastatin is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby reducing LDL cholesterol levels. The dietary component complements this pharmacological effect by reducing dietary cholesterol and saturated fat intake. Together, this combination approach addresses both endogenous and exogenous sources of cholesterol elevation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: